According to a new market study published by The Insight Partners, titled "Aesthetic Injectable Devices Market Forecast to 2031 – Global Share, Trends, and Opportunity Analysis", the global market was valued at USD 10.31 billion in 2024 and is projected to reach USD 17.58 billion by 2031, growing at a CAGR of 8.1% from 2025 to 2031.
Key Factors Driving Market Growth:
- Rising demand for non-invasive aesthetic procedures, especially among aging populations
- Technological advancements such as Cold X gels, microcannulas, and dual-weight hyaluronic acid formulations
- Expansion into high-growth regions, notably Asia-Pacific, forecasted to grow at 15.6% CAGR
- Growing adoption of tele-aesthetic platforms and digital consultations
Market Segmentation:
- By Product: Dermal Fillers, Botulinum Toxin, Others
- By Device Type: Microcannulas, Pre-Filled Syringes, Mesotherapy Guns, Others
- By Application: Facial Line Correction, Face Lift, Lip Treatment, Anti-Aging, Acne/Scar Treatment, Stretch Marks
- By Age Group: Up to 30, 31–40, 41–50, 51–60, More Than 60
- By Geography: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Recent Developments:
- May 2025: Prollenium launched Revanesse Renew+ in Canada with next-gen hyaluronic acid formulation.
- February 2025: Evolus received FDA approval for Evolysse Form and Smooth, powered by Cold X technology.
- October 2024: Allergan Aesthetics (AbbVie) gained FDA clearance for Botox Cosmetic for platysma (neck) bands.
- July 2024: Merz Aesthetics secured FDA approval for Xeomin for upper facial lines.
- May 2024: Galderma launched Restylane VOLYME and HIT protocol in China, targeting mid-face volume loss.
Leading Companies:
- Merz Pharma GmbH & Co. KGaA
- AbbVie Inc. (Allergan)
- Galderma SA
- Evolus Inc.
- Hugel Inc.
- Ipsen SA
- Medytox Inc.
- Sinclair Pharma Ltd
- Revance Therapeutics Inc.
- Mesoestetic E Commerce SL
Strategic Insights:
The market is witnessing a shift toward regionally tailored launches, digital engagement tools, and eco-conscious product design. Market leaders are focusing on regulatory alignment, localized manufacturing, and clinical innovations to gain a competitive edge.
Challenges:
Despite promising growth, the market faces regulatory complexity, supply chain risks under tariffs, intense competition, and ethical sensitivities around pricing and sustainability.
Recommendations for Stakeholders:
- Invest in R&D and new delivery systems
- Strengthen presence in emerging markets
- Build resilient, localized supply chains
- Leverage tele-aesthetics and digital education
- Prioritize regulatory compliance and sustainable practices
Get Sample PDF- https://www.theinsightpartners.com/sample/TIPRE00040973/
Conclusion
The Aesthetic Injectable Devices market is poised for robust expansion, set to grow from US$10.3 billion in 2024 to US$17.58 billion by 2031, powered by innovation, regional demand, and evolving consumer preferences. With segmentation across products, devices, applications, demographics, and geography, the sector offers rich avenues for tailored growth strategies. Key players—including Merz, AbbVie (Allergan), Galderma, Evolus, Prollenium, Ipsen, and others—are advancing through approvals, R&D, and regional launches.
Looking ahead, success hinges on blending technical innovation, regulatory acumen, market sensitivity, and supply chain agility—with digital and sustainable tactics enhancing ability to seize evolving opportunities.
